Skip to main content
SpringerLink
Log in
Book cover

Pharmacological Treatment of Acute Coronary Syndromes pp 213–237Cite as

Management of Bleeding Complications

  • Chapter
  • First Online:

  • 1395 Accesses

Part of the book series: Current Cardiovascular Therapy ((CCT))

Abstract

The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. Studies of patients receiving anticoagulant therapy indicate that the incidence of major bleeding is 0.5 %/year and intracranial bleeding 0.2 %/year, however, it is likely that in real life practice the incidence is even higher. In particular, combined anticoagulant and antiplatelet agents may markedly increase the risk of major hemorrhagic complications. The most important risk factors for bleeding in patients receiving anticoagulants are the intensity of the anticoagulation and some patient characteristics, including age and co-morbidities. In case of serious or even life-threatening bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, anticoagulant treatment can be reversed by various specific strategies. Heparin and heparin derivatives can be counteracted by protamine sulphate, whereas the anticoagulant effect of vitamin K antagonists may be neutralized with the administration of vitamin K or prothrombin complex concentrates. The anti-hemostatic effect of aspirin and other anti-platelet agents can be corrected by the administration of platelet concentrate and/or desmopressin, if needed. For the new generation oral anticoagulants including specific inhibitors of factor IIa, or factor Xa reversing strategies are currently being evaluated. The effect of factor Xa inhibitors can probably be reversed by prothrombin complex concentrates or recombinant factor VIIa, whereas for anti-IIa agents no specific reversing agent has been identified so far.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):110S–2.

    Article  PubMed  Google Scholar 

  2. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356(22):2301–11.

    Article  PubMed  CAS  Google Scholar 

  3. Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med. 2010;68(2):68–76.

    PubMed  CAS  Google Scholar 

  4. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774–82.

    Article  PubMed  Google Scholar 

  5. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007;6(2):115–24.

    Article  PubMed  Google Scholar 

  6. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P, Collet JP, Rubboli A, Poli D, Camm J. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13(5):723–46.

    Article  PubMed  Google Scholar 

  7. Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med. 2009;4(2):137–45.

    Article  PubMed  Google Scholar 

  8. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011:9(9)1705–12.

    Google Scholar 

  9. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):257S–98.

    Article  PubMed  CAS  Google Scholar 

  10. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990;322(7):428–32.

    Article  PubMed  CAS  Google Scholar 

  11. Vink R, Kraaijenhagen RA, Hutten BA, van den Brink RB, de Mol BA, Buller HR, Levi M. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol. 2003;42(12):2042–8.

    Article  PubMed  CAS  Google Scholar 

  12. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897–902.

    Article  PubMed  CAS  Google Scholar 

  13. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging. 1999;14(4):303–12.

    Article  PubMed  CAS  Google Scholar 

  14. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745–52.

    Article  PubMed  Google Scholar 

  15. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–8.

    Article  PubMed  CAS  Google Scholar 

  16. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005;2(10):e312.

    Article  PubMed  Google Scholar 

  17. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood. 2008;111(9):4471–6.

    Article  PubMed  CAS  Google Scholar 

  18. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999;9(4):215–7.

    Article  PubMed  CAS  Google Scholar 

  19. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241–50.

    Article  PubMed  CAS  Google Scholar 

  20. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333(7571):726.

    Article  PubMed  Google Scholar 

  21. Mellemkjaer L, Blot WJ, Sorensen HT, Thomassen L, McLaughlin JK, Nielsen GL, Olsen JH. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002;53(2):173–81.

    Article  PubMed  CAS  Google Scholar 

  22. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189–92.

    Article  PubMed  CAS  Google Scholar 

  23. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S–59.

    Article  PubMed  CAS  Google Scholar 

  24. Lindblad B, Borgstrom A, Wakefield TW, Whitehouse Jr WM, Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. Thromb Res. 1987;48(1):31–40.

    Article  PubMed  CAS  Google Scholar 

  25. Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis. 1986;16(2):139–46.

    PubMed  CAS  Google Scholar 

  26. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost. 1990;63(2):271–4.

    PubMed  Google Scholar 

  27. Bang CJ, Berstad A, Talstad I. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis. 1991;21(3):155–60.

    PubMed  CAS  Google Scholar 

  28. Caplan SN, Berkman EM. Letter: protamine sulfate and fish allergy. N Engl J Med. 1976;295(3):172.

    PubMed  CAS  Google Scholar 

  29. Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg. 1997;13(4):394–7.

    Article  PubMed  CAS  Google Scholar 

  30. Mauney MC, Buchanan SA, Lawrence WA, Bishop A, Sinclair K, Daniel TM, Tribble CG, Kron IL. Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine. J Vasc Surg. 1995;22(3):264–9.

    Article  PubMed  CAS  Google Scholar 

  31. Dellagrammaticas D, Lewis SC, Gough MJ. Is heparin reversal with protamine after carotid endarterectomy dangerous? Eur J Vasc Endovasc Surg. 2008;36(1):41–4.

    Article  PubMed  CAS  Google Scholar 

  32. D’Ambra M. Restoration of the normal coagulation process: advances in therapies to antagonize heparin. J Cardiovasc Pharmacol. 1996;27 Suppl 1:S58–62.

    Article  PubMed  Google Scholar 

  33. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Zimmermann JJ, Lappas DG. In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg. 1994;79(4):670–4.

    Article  PubMed  CAS  Google Scholar 

  34. Tao W, Deyo DJ, Brunston Jr RL, Vertrees RA, Zwischenberger JB. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device–an alternative to protamine. Crit Care Med. 1998;26(6):1096–102.

    Article  PubMed  CAS  Google Scholar 

  35. Buller HR. Treatment of symptomatic venous thromboembolism: improving outcomes. Semin Thromb Hemost. 2002;28 Suppl 2:41–8.

    Article  PubMed  Google Scholar 

  36. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008;111(10):4871–9.

    Article  PubMed  CAS  Google Scholar 

  37. Bijsterveld NR, Vink R, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004;124:653–8.

    Article  PubMed  CAS  Google Scholar 

  38. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Meijers JC, Buller HR, Levi M. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106(20):2550–4.

    Article  PubMed  CAS  Google Scholar 

  39. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S–98.

    Article  PubMed  CAS  Google Scholar 

  40. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;4(9):1853–63.

    Article  PubMed  CAS  Google Scholar 

  41. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Vesely S, Schulman S, Kovacs MJ, Rodger MA, Wells P, Anderson D, Ginsberg JS, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin. Ann Intern Med. 2009;150:293–300.

    Article  PubMed  Google Scholar 

  42. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002;137(4):251–4.

    Article  PubMed  CAS  Google Scholar 

  43. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469–73.

    Article  PubMed  CAS  Google Scholar 

  44. Dentali F, Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review. Haematologica. 2004;89(7):857–62.

    PubMed  CAS  Google Scholar 

  45. Aguilar MI, Hart RG, Kase CS, Freeman WD, Hoeben BJ, Garcia RC, Ansell JE, Mayer SA, Norrving B, Rosand J, Steiner T, Wijdicks EF, Yamaguchi T, Yasaka M. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82(1):82–92.

    PubMed  CAS  Google Scholar 

  46. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118(3):313–20.

    Article  PubMed  Google Scholar 

  47. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622–31.

    Article  PubMed  CAS  Google Scholar 

  48. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35:2191–5.

    Article  PubMed  CAS  Google Scholar 

  49. Levi M. New antithrombotics in the treatment of thromboembolic disease. Eur J Intern Med. 2005;16(4):230–7.

    Article  PubMed  CAS  Google Scholar 

  50. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med. 2002;162(13):1451–6.

    Article  PubMed  CAS  Google Scholar 

  51. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116(2):180–7.

    Article  PubMed  CAS  Google Scholar 

  52. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs. 2008;9(9):1020–33.

    PubMed  CAS  Google Scholar 

  53. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.

    Article  PubMed  CAS  Google Scholar 

  54. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.

    Article  PubMed  Google Scholar 

  55. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29–38.

    Article  PubMed  CAS  Google Scholar 

  56. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877–85.

    Article  PubMed  Google Scholar 

  57. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9.

    Article  PubMed  CAS  Google Scholar 

  58. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012;107(2):253–9.

    Article  PubMed  CAS  Google Scholar 

  59. Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44(3):771–8.

    Article  PubMed  CAS  Google Scholar 

  60. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost. 2012;108(2):217–24.

    Article  PubMed  CAS  Google Scholar 

  61. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation. 2002;105(8):1004–11.

    Article  PubMed  CAS  Google Scholar 

  62. Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Larson G, Eriksson H. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res. 2002;107(3–4):93–9.

    Article  PubMed  CAS  Google Scholar 

  63. Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7(7):557–8.

    Article  PubMed  CAS  Google Scholar 

  64. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–56.

    Article  PubMed  CAS  Google Scholar 

  65. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  PubMed  CAS  Google Scholar 

  66. Woltz M, Levi M, Sarich TC, Bostrom SL, Ericksson UG, Erikkson M, Svensson M, Weitz JI, Elg M, Wahlander K. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost. 2004;91:1090–6.

    Google Scholar 

  67. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, Bendszus M, Heiland S, Van RJ, Veltkamp R. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42(12):3594–9.

    Article  PubMed  Google Scholar 

  68. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):199S–233.

    Article  PubMed  CAS  Google Scholar 

  69. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis. 2004;17(1):21–7.

    Article  PubMed  CAS  Google Scholar 

  70. Richardson DW, Robinson AG. Desmopressin. [Review] [165 refs]. Ann Intern Med. 1985;103(2):228–39.

    Article  PubMed  CAS  Google Scholar 

  71. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood. 2003;102(13):4594–9.

    Article  PubMed  CAS  Google Scholar 

  72. Anonymous. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee [see comments]. Lancet. 1996;348(9038):1329–39.

    Article  Google Scholar 

  73. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  PubMed  CAS  Google Scholar 

  74. Bhatt DL. Prasugrel in clinical practice. N Engl J Med. 2009;361(10):940–2.

    Article  PubMed  CAS  Google Scholar 

  75. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723–31.

    Article  PubMed  CAS  Google Scholar 

  76. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De SS, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  PubMed  CAS  Google Scholar 

  77. Giannitsis E, Katus A. Antiplatelet therapy – ticagrelor. Hamostaseologie. 2012;32:177–85.

    Article  PubMed  CAS  Google Scholar 

  78. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

    Article  PubMed  CAS  Google Scholar 

  79. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack Jr CV, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330–41.

    Article  PubMed  CAS  Google Scholar 

  80. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack Jr CV, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318–29.

    Article  PubMed  CAS  Google Scholar 

  81. Grines CL, Bonow RO, Casey Jr DE, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc Interv. 2007;69(3):334–40.

    Article  PubMed  Google Scholar 

  82. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007;5(1):82–90.

    Article  PubMed  CAS  Google Scholar 

  83. Leithauser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. Clin Hemorheol Microcirc. 2008;39(1–4):293–302.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105, AZ, The Netherlands

    Marcel Levi MD, PhD

Authors
  1. Marcel Levi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcel Levi MD, PhD .

Editor information

Editors and Affiliations

  1. Servicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Spain

    Pablo Avanzas

  2. Department of Cardiology, The Heart Center, Rigshospitalet University Hospital of Copenhagen,, Copenhagen, Denmark

    Peter Clemmensen

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Levi, M. (2014). Management of Bleeding Complications. In: Avanzas, P., Clemmensen, P. (eds) Pharmacological Treatment of Acute Coronary Syndromes. Current Cardiovascular Therapy. Springer, London. https://doi.org/10.1007/978-1-4471-5424-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5424-2_7

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5423-5

  • Online ISBN: 978-1-4471-5424-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation